Novavax Stock Hits 2-Year Low As Challenges Mount For Covid Shot
Novavax stock is trading at a two-year low amid slowly ramping use of its Covid vaccine, dubbed Nuvaxovid, in the U.S.
The Food and Drug Administration signed off on Nuvaxovid in July, six months after Novavax (NVAX) asked the agency to authorize the regimen for emergency use. Since then, just 6,278 people have received two doses of the vaccine, according to the Centers for Disease Control and Prevention.
In total, Novavax has delivered roughly 31.2 million doses of the shot in the…